Insulin resistance in polycystic ovary syndrome across various tissues: an updated review of pathogenesis, evaluation, and treatment

Abstract

Polycystic ovary syndrome (PCOS) is a common endocrine disorder characterized by chronic ovulation dysfunction and overabundance of androgens; it affects 6–20% of women of reproductive age. PCOS involves various pathophysiological factors, and affected women usually have significant insulin resistance (IR), which is a major cause of PCOS. IR and compensatory hyperinsulinaemia have differing pathogeneses in various tissues, and IR varies among different PCOS phenotypes. Genetic and epigenetic changes, hyperandrogenaemia, and obesity aggravate IR. Insulin sensitization drugs are a new treatment modality for PCOS. We searched PubMed, Google Scholar, Elsevier, and UpToDate databases in this review, and focused on the pathogenesis of IR in women with PCOS and the pathophysiology of IR in various tissues. In addition, the review provides a comprehensive overview of the current progress in the efficacy of insulin sensitization therapy in the management of PCOS, providing the latest evidence for the clinical treatment of women with PCOS and IR.

Background

Polycystic ovary syndrome (PCOS) is currently recognized as the most common endocrine disorder in women of reproductive age, with a worldwide prevalence ranging from 6 to 21%, depending on the diagnostic criteria [1–5]. PCOS is a heterogeneous disease characterized by hyperandrogenism, dysfunctional ovulation, and polycystic ovary morphology, accompanied by metabolic abnormalities, such as insulin resistance (IR) and obesity. However, the underlying pathogenesis of PCOS remains unclear. Recent studies have suggested that genetics, epigenetic changes, environmental factors, oxidative stress, chronic low-grade inflammation, mitochondrial dysfunction, and metabolic disorders are involved in PCOS, thus damaging normal ovarian function [6–13]. IR and compensatory hyperinsulinaemia (HI) are considered major drivers of PCOS pathophysiology and are involved in the development of hyperandrogenaemia and reproductive dysfunction by various mechanisms [14].

IR and compensatory hyperinsulinaemia (HI) are present in 65–95% of women with PCOS, including the vast majority of overweight and obese women and more than half of women of normal weight. IR is independent of and exacerbated by obesity [14–18]. Currently, there are four commonly recognized phenotypes of PCOS: type A, polycystic ovary (PCO), chronic oligo-anovulation (OA) and hyperandrogenism (HA); type B, OA and HA; type C, PCO and HA; and type D, PCO and OA [19]. IR is present in all phenotypes, and insulin sensitivity varies according to the PCOS phenotype. IR is the most common classical phenotype (Types A and B) (80%), followed by ovulating PCOS (65%) and non-hyperandrogenaemic PCOS (38%) [20]. Women with PCOS and IR have a significantly increased risk of adverse pregnancy outcomes [21, 22] and chronic diseases, such as type 2 diabetes mellitus (T2DM), cardiovascular disease, and metabolic syndrome, which seriously affect the physical and mental health of women of childbearing age, increasing their social burden [23–25]. However, the root cause of IR in PCOS is largely unknown and the underlying mechanism remains to be elucidated. Therefore, recognizing the strong influence of IR on the occurrence and development of PCOS, accurate assessment of insulin sensitivity in the early stages of PCOS, and effective intervention on IR are essential to reduce the risk of long-term complications. Lifestyle change is the treatment of choice for all women with PCOS, and insulin sensitization is a promising choice for the chronic treatment of women with PCOS. This paper aims to summarize recent findings on the involvement of IR in the occurrence and development of PCOS and the mechanism of IR in various tissues. Furthermore, we aim to summarize and provide an update on the current research status of insulin sensitization therapy for women with PCOS to provide more effective and reasonable clinical treatment.

Methods

An extensive literature search was performed up to July 2022 in PubMed, Google Scholar, Elsevier, and UpToDate databases. Keywords and subject terms included (“PCOS” AND “insulin”) OR (“PCOS” AND “insulin” AND “tissues”) OR (“PCOS” AND “insulin” AND “pathogenesis”) OR (“PCOS” AND “insulin” AND “diagnosis”) OR (“PCOS” AND “insulin” AND “evaluation”) OR (“PCOS” AND “insulin” AND “therapy”). Only English-language research papers were considered. In addition, publications focus on the new ones (since 2018) and exclude those without full manuscripts.

Pathogenesis of insulin resistance in polycystic ovary syndrome

Genetics and foetal origin

PCOS is an autosomal dominant genetic disease with various expression patterns that begins in early life, and metabolic changes precede reproductive abnormalities. A clustering analysis of 893 women with PCOS identified the metabolic subtype of PCOS, which was characterized by higher BMI and glucose and insulin levels with relatively low SHBG and LH levels [5]. IR is one of the prominent phenotypic characteristics of PCOS [26]. Twin and family cluster studies have suggested HI has a genetic component in PCOS, and a family history of T2DM is associated with significant insulin secretion defects [27, 28]. The daughters of women with PCOS develop HI and lower adiponectin levels before puberty [29], which persist throughout adolescence [30].

PCOS is associated with specific gene mutations, and most gene variants identified in genome-wide association studies are involved in regulating sheath steroid production, follicular maturation, or insulin signalling through the modified proteins they encode, such as insulin receptors, LH/HCG receptor activators, cell traffic proteins, and transcription factors [31, 32]. Genome-wide association studies on European, Chinese, and Indian populations have established that some insulin receptor (INSR) gene variants (rs2059807 and rs1799817) are significantly associated with IR in women with PCOS [33, 34]. Studies of Indian women suggest that C/T polymorphisms in the INSR tyrosine kinase domain may be susceptible variants in women with normal-weight PCOS, contributing to the development of IR and compensatory HI [35]. A meta-analysis showed that the Gly972Arg polymorphism in insulin receptor substrate 1 (IRS-1) mediates the pathogenesis of PCOS by increasing fasting glucose levels and is a risk factor for susceptibility to PCOS [36, 37]. However, the genetic assessment of insulin-related genes is affected by the diagnostic criteria and genotyping methods employed with patients, resulting in different results [38]. Exposure to adverse intrauterine environments can lead to varying degrees of IR and HI. Exposure to dihydrotestosterone and insulin in the second trimester of pregnancy produces a PCOS-like phenotype and increases the risk of miscarriage [39]. Intrauterine growth restriction can affect foetal insulin secretion, and insulin resistance trends in PCOS may be involved in developmental origin and preprogramming as a nutritional compensation mechanism [40, 41]. Adolescents and young women with a history of low birth weight are more likely than normal women to have PCOS-like manifestations of IR and high androgen levels [42, 43].

Insulin signal transduction pathway

Insulin is a small peptide receptor-binding hormone released by pancreatic beta cells, which binds to cell surface receptors. INSR is a heterotetramer composed of α- and β-subunits linked by disulphide bonds. The extracellular α-subunit is responsible for binding to the ligands. The β-subunit is a glycoprotein spanning the cell membrane with tyrosine kinase activity [44]. Insulin binding to receptors induces specific tyrosine autophosphorylation, which phosphorylates intracellular substrates, including IRS1-4, SRC homologues, and collagen homologues (Shc), leading to a complex intracellular cascade that initiates insulin signal transduction [45]. Insulin has two main signalling pathways: metabolism and mitosis. Metabolism is primarily mediated through phosphatidylinositol 3-kinase (PI3-K) and serine/threonine kinase Akt/protein kinase B (PKB), also known as the PI3-K pathway. Through these pathways, insulin stimulates glucose uptake by promoting the translocation of glucose transporter 4 (GLUT4) from intracellular vesicles to the cell surface [46] and leads to the inactivation of serine phosphorylation of glycogen synthase kinase 3 (GSK3), increasing glycogen, fatty acid, and protein synthesis. It also activates mammalian target of rapamycin (mTOR) to regulate protein synthesis and degradation [46]. The mitotic pathway is the mitogen-activated protein kinase-extracellular signal-regulated kinase (MAPK-ERK) pathway, which is activated by insulin receptor-mediated phosphorylation of Shc or IRS. This progressively stimulates the translocation of cascade erk1/2 to the nucleus and phosphorylates transcription factors to stimulate cell growth and differentiation and regulate gene expression [47, 48]. Increased serine phosphorylation and decreased tyrosine phosphorylation of insulin receptors and IRS can terminate insulin action, resulting in post-binding defects in insulin signal transduction and leading to insulin dysfunction in women with PCOS [49, 50].

Hyperinsulinaemia and tissue insulin resistance

IR in PCOS is caused by impaired insulin action in various target tissues, which is characterized by basal compensatory HI and a reduced insulin response to glucose overload. PCOS affects the majority of organ systems and tissues. Insulin plays different roles in different tissues in balancing the supply and demand of nutrients. HI caused by tissue IR is central to PCOS pathology [51]. IR in women with PCOS selectively and mutually affects metabolism or mitotic pathways in classical insulin target tissues (e.g., liver, skeletal muscle, and adipose tissue) and non-classical insulin target tissues (e.g., ovary, pituitary gland) [52]. In addition, androgen overload, lipid deposition, inflammatory cytokines, and other systemic factors are also involved in the IR process of peripheral tissues [53] (Fig. 1).

Adipose tissue

Adipose tissue plays a central role in systemic glucose metabolism and insulin sensitivity. Compared with body mass index (BMI)-matched control women, women with PCOS showed systemic fat accumulation and significantly increased subcutaneous fat cell volume, whereas visceral fat volume was only increased in PCOS phenotype A [54–56]. The increase in adipose tissue volume, especially visceral adipose tissue volume, is closely associated with whole-body IR [57]. The IR of adipose tissue results in decreased glucose uptake and lipid accumulation, and significantly inhibits lipid decomposition. Excessive fatty acids flow into skeletal muscle and liver, resulting in lipid storage and aggravating IR of skeletal muscle and the liver [58].

Adipose tissue IR in women with PCOS is influenced by circulating androgen levels and excessive energy intake. Androgens induce adipocyte IR by affecting the phosphorylation of insulin-stimulated protein kinase C (PKC), leading to a decrease in insulin-induced GLUT-4 content in PCOS abdominal subcutaneous adipocytes and a decrease in insulin-stimulated serine phosphorylation of GSK3, indicating the presence of insulin receptor binding or phosphorylation defects in adipocyte IR [59]. This impairs the effect of insulin on glucose metabolism but does not affect insulin-induced mitosis [59]. Androgens also regulate lipid metabolism and adipocyte differentiation, and induce the accumulation of abdominal adipose tissue. Animal models have shown that prenatal and postnatal exposure to androgens can lead to enlargement of adipocytes, accumulation of visceral fat, and decreased insulin sensitivity in women [60, 61]. In addition, testosterone is specific to catecholamine-stimulated lipolysis and can reduce the sensitivity of human subcutaneous fat cells but not visceral fat cells [62].

Type 1C3 aldosterone reductase (AKR1C3) is the only enzyme expressed in adipose tissue that can convert androstenedione into testosterone, which is widely expressed in the adipose tissue of patients with PCOS [63]. Studies have shown that AKR1C3 is the main driver of active androgen production in PCOS adipose tissue [63]. In addition, AKR1C3 expression is regulated by insulin [64], suggesting a significant correlation between testosterone and circulating insulin levels in adipose tissue. Increased androgen production in adipose tissue and subsequent lipid accumulation and fat mass can lead to systemic IR and lipotoxic organ damage in patients with PCOS [63]. HI further exacerbates hyperandrogenaemia, resulting in a vicious cycle that exacerbates poor metabolic performance [63]. In addition, free testosterone seen in PCOS is inversely proportional to the serum level of high-molecular-weight adiponectin, a collagen-like protein synthesized only by adipose cells, which has insulin sensitization and anti-inflammatory effects and decreases with adipose tissue volume [65]. Decreased adiponectin levels result in decreased PKC activity and insulin signalling [66]. Adiponectin also stimulates the secretion of hepatic sex hormone-binding globulin (SHBG), suggesting that the effect of androgen’on adipose IR may be influenced by hepatic SHBG through serum free testosterone levels [66]. Increased adipose tissue and its dysfunction may exacerbate physiological factors and cytokine levels, such as leptin, interleukin 6, and tumour necrosis factor alpha, thereby promoting low-level inflammation, interfering with insulin signalling, causing adipose tissue to release free fatty acids, increasing ectopic fat deposition, and aggravating IR on one’s own and other organizations [67–69].

Skeletal muscle

Skeletal muscle is responsible for most peripheral glucose uptake regulation, and almost two thirds of the glucose intake after meals is absorbed by skeletal muscle through insulin-dependent mechanisms, making it the most important insulin-resistant tissue [70]. Muscle insulin-mediated glucose processing, as measured by a normal glucose clamp, was significantly reduced in all women with PCOS compared to women without PCOS [71]. Skeletal muscle IR in women with PCOS is reflected by impaired insulin-stimulated glucose processing, which is a major risk factor for T2DM in women with PCOS [51]. However, human studies have not yet determined the molecular mechanism of PCOS-specific IR in skeletal muscle, and there have been many conflicting findings. The potential mechanisms currently considered include genetic and epigenetic programming, signalling pathway and mitochondrial dysfunction, intracellular and extracellular lipid accumulation, and organ system crosstalk [72].

Initial studies of muscle tissue and cultured myoducts and fibroblasts [73, 74] found elevated phosphorylation of serine residues on IRS1/2, resulting in the translocation of GLUT4 and reduced glucose uptake, suggesting defective signalling at the proximal insulin site. Skeletal muscle biopsies of women with PCOS revealed a significant decrease in insulin-mediated IRS1-related PI3-K activation, with an increase in IRS2 abundance as a compensatory change after targeted IRS1 destruction. Subsequent skeletal muscle studies showed decreased phosphorylation of Akt/PKB and the Akt substrate 160-KDA (AS160) [75]. These studies in obese women with PCOS suggest that possible PCOS-specific defect in insulin signaling of skeletal muscle is proximal and distal to IRS1/2. Hansen et al. studied molecular mechanisms in skeletal muscle underlying IR in normal-weight women with PCOS, finding that decreased insulin sensitivity may only play a role in skeletal muscle IR through AMPK and is associated with low circulating adiponectin levels [76]. In addition, a lack of insulin-stimulated pyruvate dehydrogenase activation in skeletal muscle may lead to reduced systemic metabolic flexibility and mediation of IR through metabolic signalling pathways [76]. Furthermore, constitutive activation of the mitotic signal MAPK-ERK1/2 has also been found in skeletal muscle biopsies of women with PCOS, which promotes serine phosphorylation of IRS1 and reduces metabolic signalling in PCOS myotube [77], suggesting that IR may impact both the metabolic and mitotic pathways in skeletal muscle of women with PCOS.

Animal studies have shown that hyperandrogenaemia promotes IR by increasing serine phosphorylation of Akt/PKB, mTOR ribosomal S6 kinase, and IRS1 in myotubes and promoting visceral fat accumulation [78]. In addition, hyperandrogenaemia may increase inflammation by activating nuclear factor kappa B (NF-κB), which in turn affects intracellular enzyme pathways associated with insulin receptors [51]. A recent meta-analysis suggested that obesity, but not HA or IR, appears to predict skeletal muscle mass in reproductive-aged women with PCOS [79]. Intramuscular lipid accumulation within muscle cells or between fibres may account for a small percentage of skeletal muscle IR [80]. PCOS is associated with abnormal skeletal muscle gene expression, and it is affected by specific changes in DNA methylation [72]. Furthermore, a link between TGF-β superfamily ligand signalling and extracellular matrix deposition in PCOS-specific IR results in inappropriate crossing between these cells and their host organs, suggesting that epigenetic as well as tissue crossing is involved in skeletal muscle metabolic abnormalities [72]. Mitochondrial oxidative phosphorylation genes are downregulated in the skeletal muscle of women with PCOS, suggesting that mitochondrial dysfunction is involved in PCOS-specific IR formation [72, 81].

Liver tissue

The liver is also the main site of glucose uptake and storage, accounting for one third of postprandial glucose processing, and the main site of insulin clearance [81]. Insulin in the liver promotes glycogen synthesis and de novo lipogenesis while also inhibiting gluconeogenesis. PCOS-related hepatic IR is usually only present in obese women, leading to a deficiency in insulin-stimulated liver glycogen synthesis and insulin-mediated inhibition of hepatic glucose production [82]. IR and compensatory HI can directly inhibit the synthesis of liver SHBG and insulin growth factor 1 (IGF1) binding protein. The former is a glycoprotein synthesized mainly in the liver, and its reduced synthesis leads to increased free testosterone levels [83]. The reduction of the latter increases the circulating concentration of IGF1, which not only triggers the ovarian membrane cells to produce more androgens, but also reduces specific microRNAs, thus accelerating the apoptosis of granulosa cells and inhibiting follicular development. These two effects together lead to hyperandrogenaemia and follicular development disorders in PCOS [13].

Insulin in the liver can directly regulate glucose and lipid metabolism and can also be indirectly regulated by fat and muscle insulin action. Direct effects activate de novo lipogenesis, convert excess carbohydrate substrates to triglycerides, and promote liver triglyceride delivery to adipose tissue [82]. Indirect effects are mainly caused by insulin-mediated inhibition of lipolysis in adipose tissue, which leads to an increase in circulating plasma non-fatty acids in the liver and promotes fat deposition in the liver. Approximately 59% of the lipids in hepatocytes are derived from non-fatty acids produced by adipolysis [82]. The liver-specific insulin receptor knockout (LIRKO) mouse model suggests that the insulin signalling is essential for the regulation of glucose homoeostasis in the liver and maintenance of normal liver function [84]; further, it is also a prerequisite for the indirect regulation of adipose insulin. LIRKO mice still showed obvious IR, severe glucose intolerance, and resistance to insulin’s ability to inhibit liver sugar production under the premise of normal insulin signal transduction in fat and muscle tissues [82]. In addition, hepatic lipid accumulation activates diacylglycerol/PKC and inhibits insulin receptors, affecting insulin signalling and subsequent gluconeogenesis, thereby exacerbating hepatic IR [53].

In vitro and in vivo studies of liver-specific androgen receptor (AR) gene knockout have found that AR signalling in liver cells mediates hepatic IR in hyperandrogenaemia-induced female mice through a cascade of changes in hepatic insulin signalling and phosphorylation, suggesting that androgens are involved in hepatic IR [85]. Long-term androgen excess can induce hepatic insulin resistance and steatosis in PCOS-like rats. Under hepatic IR, excessive androgens can promote the development of non-alcoholic fatty liver disease (NAFLD) through apoptosis and autophagy in the liver mitochondria [86]. NAFLD, a metabolic syndrome characterized by abnormal fat accumulation, is now considered the most common chronic liver disease in the United States, and its prevalence in PCOS has increased significantly in recent years [87]. Several human studies have shown a close association between NAFLD and liver IR, and IR is an important risk factor for NAFLD in PCOS [88–90].

The ovaries and uterus

Ovarian androgen overload is the core of PCOS. HI enhances intrathecal steroid production and leads to impaired follicular maturation. Insulin receptors are widely distributed in stromal and follicular ovarian cells, and there is considerable evidence for the direct ovarian effect of insulin on steroid production and the importance of insulin-signalling pathways in ovulation control [91, 92]. Under physiological conditions, insulin acts as a helper gonadotropin through its homologous receptor to increase LH-induced androgen synthesis in membrane cells, and LH induces luteinization in granulosa cells [93]. HI can lead to androgen-dependent anovulation via different mechanisms. Membrane cells are the main site of androgen production in the ovaries. Insulin acts on the membrane cells of the ovary to directly trigger androgen synthesis by increasing the activity of cytochrome P450c17α, a key enzyme that regulates androgen biosynthesis encoded by CYP17. Insulin can also cooperate with LH. The 17α-hydroxylase activity of P450c17 is activated by PI3-K signalling to induce androgen synthesis in membrane cells [94–97]. The membrane cells of women with PCOS are more sensitive to the hyperandrogenic effects of insulin than healthy women [51]. In anovulatory PCOS granulosa cells, the synergistic effect of high insulin and LH levels may induce premature expression of LH receptors in small follicular subsets, leading to premature differentiation of granulosa cells and follicular growth stagnation [98]. The effect of insulin on glucose metabolism was significantly reduced in granular lutein cells isolated from the ovaries of women with typical PCOS phenotypes, whereas the effect of insulin on steroid production was unchanged [98]. Reduced phosphorylation of MEk1/2 and MApK-ERk1/2 in PCOS was associated with increased P450c17 expression compared with that in normal membrane cells, contrary to the findings of increased phosphorylation of MEk1/2 and MApK-ERk1/2 in PCOS skeletal muscle [74]. These results suggest the existence of selective insulin resistance in PCOS ovarian tissue.

Energy metabolism is also critical for normal endometrial function, and endometrial studies of patients with PCOS have shown that IR and HI also negatively affect endometrial physiology. Endometrial tissues express molecules involved in insulin signalling pathways, and the expression of insulin receptors, IRS proteins, AS160, PKC, and GLUT4 in the endometrium of women with PCOS is impaired and associated with adverse reproductive outcomes [39]. Hyperinsulinaemia can impair decidualization of endometrial stromal cells in vitro through the transcriptional inhibition of FOXO-1 [99]. In addition, hyperandrogenaemia plays a role in the insulin signalling pathway of the endometrium, reducing the expression of INRS-1 and GLUT-4 in endometrial glandular epithelial cells [100]. The insulin sensitizer metformin promotes GLUT4 transcription by increasing AMPK, improves IR, and indirectly restores endometrial function in PCOS patients [101].

Central nervous system

Insulin affects the hypothalamic-pituitary system and can increase the frequency and amplitude of gonadotropin-releasing hormone (GnRH) release pulses through MAPK and increase GnRH gene expression, thereby increasing LH release, enhancing androgen biosynthesis in the ovary, and impairing ovarian function [102]. Insulin signalling in the central nervous system plays an important role in normal reproduction and body weight regulation. Female mice with neuron-specific destruction of IR genes show increased food intake, disrupted LH release, and impaired ovarian follicle maturation [103, 104]. Leptin, one of the earliest known adipokines, is essential in the hypothalamus for maintaining normal body weight and insulin sensitivity [105]. Specific knockout of insulin receptors and leptin receptors in hypothalamic proopiomelanocortin neurons induces a PCOS phenotype [106]. The pituitary gland is one of the most important components of the PCOS insulin. Insulin can directly stimulate LH secretion, leading to abnormal reproductive function in PCOS patients [107]. In addition, IR- and HI-mediated reduction of pituitary sensitivity to GnRH and disruption of pituitary insulin receptors can lead to anovulation [108]. Women with PCOS had a higher ACTH response to corticotropin-releasing hormone (CRH) stimulation than women who ovulate normally, which was strongly associated with HI severity [109]. IR and compensatory HI can increase adrenal androgen levels and aggravate PCOS hyperandrogenaemia by increasing adrenal sensitivity to ACTH [110].

Women with PCOS show hyperactivation of the AR in the preoptic area, hypothalamus, and other limbic structures [110]. Animal studies have found that male mice with neuronal AR deletions exhibit hypothalamic IR, suggesting that androgens may also promote IR by acting on the central nervous system [111]. In addition, increased leptin expression in the hypothalamus can aggravate obesity, and enhanced leptin secretion by adipocytes can further contribute to the induction of IR [48]. the two interact to cause metabolic disorders in PCOS.

Factors affecting insulin resistance in polycystic ovary syndrome

Epigenetic changes (DNA methylation, histone status, and miRNA expression) are involved in the regulation of IR in women with PCOS. A study identified 79 differentially methylated genes in women who have PCOS with or without IR [112], and hypermethylation of the LAMIN gene promoter was associated with IR in PCOS [113]. MicroRNAs (miRNAs) are small non-coding RNA involved in the post-transcriptional regulation of genes. As regulators of gene expression, miRNAs are essential genes involved in the control of androgen synthesis, inflammation, adipogenesis, and signalling [114]. There are significant differences in miRNA expression levels between women with PCOS and healthy women [114]. Studies have shown that microRNAs secreted into the circulation by adipocyte exosomes and adipose tissue macrophages affect the PI3K/Akt-GLUT4 signalling pathway [115]. Mir-155-5p and related target genes of PCOS are concentrated in the insulin-sensitive pathway of the ovary, and Mir-222 is also positively correlated with serum insulin levels, suggesting their potential value as biomarkers of PCOS [115].

Insulin sensitivity can also be negatively affected by changes in diet, the environment, and mood. Recent studies suggest that an imbalance of intestinal flora and abnormal levels of metabolites produced by bacteria in individuals with may lead to insulin receptor signalling deficiency, leading to IR by causing immune system dysfunction, the development of chronic low-grade inflammation, and the enhancement of proinflammatory cytokine synthesis [116]. Vitamin D deficiency can also affect insulin signalling in tissues by affecting intracellular calcium regulation and exacerbating inflammatory responses [117, 118]. Melatonin is involved in regulating insulin secretion, and decreased melatonin secretion at night is associated with increased IR [119]. In addition, melatonin’s action is mediated by the melatonin receptor (MTNR), and activation of the MTNR1B signalling pathway in pancreatic beta cells reduces insulin secretion [120–122]. A meta-analysis also showed that MTNR1B RS1083096 and RS2119882 are involved in the pathogenesis of IR in Chinese women with PCOS [123]. Advanced glycation end products alter cellular translocation of insulin intracellular signalling and glucose transporters in PCOS through a variety of mechanisms, leading to tissue IR [124]. The endocrine disruptor bisphenol A also disrupts glucolipid metabolism and induces IR in PCOS by altering insulin secretion, adipocyte differentiation, and adipokine secretion [125]. In addition, chronic stress can trigger the release of cortisol from the hypothalamic–pituitary–adrenal axis, which can stimulate visceral fat accumulation, gluconeogenesis, and lipolysis, leading to IR [126, 127].

Diagnosis and evaluation of insulin resistance in polycystic ovary syndrome

The glucose clamp technique is the ‘gold standard’ for evaluating metabolic insulin resistance in vivo. The amount of glucose injected in the steady state was equal to the amount of glucose absorbed by the peripheral tissue, which can be used to measure peripheral sensitivity to insulin [128]. Minimal model analysis using a frequently sampled intravenous glucose tolerance test (FSIGT) is an alternative to the simplified clamp procedure for assessing insulin secretion in insulin sensitivity experiments [129]. However, both the clamp test and FSIGT are complex, time-consuming, and expensive sampling procedures that are unsuitable for clinical practice. In recent years, clinical practice has developed many simple, cheap, and effective alternative quantitative indicators, such as BMI, waist circumference, waist-to-hip ratio, wrist circumference [130]and other anthropometric markers; fasting insulin, oral glucose tolerance test (OGTT), glucose/insulin ratio (G/I), homoeostasis model assessment of insulin resistance (HOMA-IR), quantitative insulin sensitivity test index (QUICKI) [131], lipid/lipoprotein ratio [132–134]and other biomarkers. These indices are reasonably correlated with each other and with the gold standard clamp technique. HOMA-IR is currently the best and most widely validated marker, but the cut-off point for the diagnosis of PCOS-IR is still not universally accepted [135]. Studies suggest that a more complex evaluation of the decrease in insulin sensitivity as a continuous variable is required in clinical practice [10]. In addition, owing to the strong association between inflammation and IR, inflammatory markers such as interleukin-6 (IL-6) [136] and ferritin [137] are becoming increasingly popular in the evaluation of IR, while cytokines such as leptin [138] and adiponectin [139] have also been proposed as new IR markers. However, conflicting data limit their use in clinical settings, and more studies are needed to clarify their suitability as IR markers in patients with PCOS [140].

Treatment of insulin resistance in polycystic ovary syndrome

Lifestyle change

Guidelines recommend that once women are diagnosed with PCOS and have decreased insulin sensitivity, they should make lifestyle changes and start insulin sensitivity treatment immediately, even if there are no significant changes in glucose tolerance [141]. The first step in managing IR is lifestyle change, which is the cornerstone of improving multiple endocrine and metabolic disorders in women with PCOS [142] and can be achieved through appropriate diet and exercise recommendations [143]. Studies on the relationship between caloric intake and expenditure in women with PCOS have been inconsistent, with preliminary data suggesting that the diets of women with PCOS tend to be high in carbohydrates and fat [144], with decreased satiety and increased sweet cravings [145]. Calorie-restricted diets may be the best option for reducing IR and improving body composition [146]. Studies have shown that the Mediterranean diet—which emphasizes a high intake of vegetables, fruits, seafood, legumes, and nuts; whole grains as staple foods; and the promotion of vegetable oils—combined with a low-carbohydrate regimen improves endocrine disorders and menstrual cycles in overweight patients with PCOS [147]. International evidence-based guidelines recommend that all women with PCOS, especially those who are overweight or obese, engage in at least 150 min of aerobic exercise per week, including more than 90 min of vigorous exercise [148]. There have been conflicting conclusions regarding the efficacy of the choice of optimal exercise mode in improving insulin sensitivity in women with PCOS. The heterogeneity of PCOS necessitates individualization of treatment options, and it appears that exercise combined with additional dietary/drug intervention is better for improving insulin sensitivity than either intervention alone [149–151].

Sleep deprivation is associated with an increased risk of IR, obesity, and T2DM in women with PCOS; therefore, sleep management should also be part of lifestyle change in women with PCOS [152]. Ensuring adequate, high-quality sleep can be an important initial change in women with PCOS. Since IR is strongly and independently associated with depression in PCOS, lifestyle interventions should be supported by mental health professionals who can provide appropriate psychological care for women with PCOS [25]. PCOS treatment is a long-term process, and diet and physical exercise require high self-discipline, are time-consuming, and are prone to relapse. Targeting IR is an effective strategy for treating PCOS. Clinical and experimental studies in recent years have explored several promising new therapies for improving IR in women with PCOS. Common pharmacological approaches for reducing IR in women with PCOS are outlined in the chart below (Table 1).

Insulin sensitization therapy

Metformin

Metformin, the most widely used insulin sensitizer for PCOS, reduces hepatic glucose production, inhibits gluconeogenesis and adipogenesis, improves peripheral tissue sensitivity to insulin, and prevents excessive insulin activity in the ovary [153]. Numerous studies have shown that metformin not only reduces weight and metabolic disorders but also corrects menstrual patterns, restores ovulation, and even improves chances of pregnancy [154]. Evidence-based guidelines recommend the use of metformin in obese, insulin-resistant women with PCOS to manage weight and endocrine and metabolic disorders, in conjunction with lifestyle adjustments [155, 156]. Metformin improves insulin sensitivity, alleviates metabolic disorders, and ameliorates polycystic symptoms in mice with PCOS by increasing the translocation of the glucose transporters GLUT1 and GLUT4 to cell membranes [157], activating the AMPK signalling pathway [158], and reconstructing the role of endogenous insulin-sensitizing molecules, such as adiponectin, in endometrial tissues under pathological conditions [159]. However, metformin use may be limited by gastrointestinal side effects [160].

Thiazolidinediones

Thiazolidinediones (TZDs) and peroxisome proliferator-activated receptor γ (PPAR-γ) agonists are true insulin sensitizers. PPAR-γ is a nuclear receptor that enhances insulin activity through a post-insulin receptor mechanism, primarily by improving insulin sensitivity in the adipose tissue and skeletal muscle [213]. TZDs can be used as alternative drug therapy for PCOS-related metabolic and reproductive abnormalities in women who cannot tolerate or respond poorly to metformin [161, 162, 213]. TZDs are effective as treatments for HI and IR in both lean and obese women with PCOS as well as in improving abnormal glucose tolerance, hyperandrogenaemia, and ovulation disorders in women with PCOS. Several studies and our mesh meta-analysis suggest that TZDs improve IR and dyslipidaemia in PCOS more than metformin does [163, 214, 215]. In addition, the combination of metformin and TZDs has a synergistic effect in the treatment of women with PCOS, conferring greater improvement in IR and menstrual frequency in PCOS than metformin alone [215]. Women with dyslipidaemia and PCOS may also consider rosiglitazone alone or in combination with low-dose metformin and lifestyle changes [119]. Compared to trioglitazone and rosiglitazone, pioglitazone shows a higher affinity for the specific receptor PPAR-γ, has more effective insulin sensitization and lower hepatotoxicity, but does not promote weight loss [109].

New antidiabetic drugs

Many new antidiabetic drugs have shown positive effects in the treatment of PCOS. Glucagon-like peptide-1 analogues (GLP-1RAs) mimic the incretin secreted by the distal small intestine, bind to insulin receptors on beta cells, stimulate insulin secretion, reduce glucagon secretion, inhibit hunger centres, and delay gastric emptying. They also exhibit anti-inflammatory properties [216, 217]. Recent studies have shown that GLP-1RAs therapy has excellent therapeutic effects in improving hyperandrogenaemia, increasing menstrual frequency, reducing manifestations of metabolic disorders such as obesity and IR, and reducing long-term cardiovascular risk in obese women with PCOS [164, 166]. The combination of GLP-1RAs and metformin appears to be superior to any single agent in reducing body weight, hyperandrogenaemia, IR, and ovulation disorders in women with PCOS and may even improve metabolic outcomes in women who previously had an inadequate response to metformin [162, 217]. However, most GLP-1RAs are administered subcutaneously. Simultaneously, correct administration of medication is crucial to reduce the occurrence of adverse reactions [164, 165, 167, 168, 218]. Sitagliptin, a DPP-4 inhibitor, enhances early insulin secretion by reducing incretin and GLP-1 degradation, reduces peak glucose after oral glucose intake in overweight women with PCOS, and improves visceral obesity [169].

Sodium-glucose cotransporter type 1 and type 2 inhibitors (SGLT1/2is) play important roles in glucose homoeostasis by reducing HI and improving IR by acting on glucose (heavy) absorption in the gut and kidney, respectively [219]. Although the mechanism of action of SGLT1/2is in PCOS has not been fully investigated, weight loss and HI, improved IR and glucose metabolism, and cardioprotective effects are beneficial in PCOS, suggesting that SGLT1/2is may be a novel treatment option [170–172]. In clinical trials, the SGLT2 inhibitor canagliflozin was not inferior to metformin in reducing HOMA-IR, and canagliflozin also significantly improved menstruation and body weight and reduced triglyceride levels, suggesting that it should be considered an effective treatment for patients with PCOS and IR [173]. Urinary symptoms are major adverse events associated with SGLT2 inhibitors, and more large-scale randomized controlled trials are expected to be published in the future to explore their therapeutic potential for PCOS [220].

Natural molecules and dietary supplements

Inositol is a compound with nine forms (sugar alcohols), of which inositol (MI) and d-chiral inositol (DCI) are the most abundant forms present in humans, playing important biological roles in mediating various effects of insulin. Several scientific studies have confirmed that it has excellent insulin sensitization efficiency in women with PCOS and promotes ovulation [180]. Given that inositol administration is safe and effective in ameliorating the reproduction and metabolism of patients with PCOS, it may be used not only as a treatment for infertile women but also as a preventive treatment during pregnancy [180–183]. Appropriate application of MI and a suitable proportion of DCI improves the health of organs and tissues, while long-term high-dose DCI monotherapy in women with PCOS has a negative impact [184]. Therefore, inositol treatment should be evaluated according to the specific situation and needs of patients, while its optimal ratio still needs to be further clarified and supported by large-scale clinical trials and pharmacokinetic studies to better adjust supplement doses [185].

Alpha-lipoic acid [186] and omega-3 fatty acids are two supplements that improve lipid and insulin sensitivity in women through their anti-inflammatory and antioxidant properties, although omega-3 fatty acids are high in calories [187]. Studies suggest that coenzyme Q10 has beneficial effects on glucose and lipid metabolism, insulin, HOMA-IR, and total testosterone levels in women with PCOS and can also improve ovarian function [188–190]. Vitamin E combined with coenzyme Q10 can improve IR and serum SHBG levels in PCOS [191, 192]. Supplementation with probiotics, prebiotics, and synbiotics in women with PCOS can improve IR, protect the intestinal barrier, and regulate the immune system, lipid profile, and other metabolic disorders [193, 194]. Recent studies have also found that a high-fibre diet consisting of whole grains, traditional Chinese medicinal foods, and prebiotics combined with the α-glucosidase inhibitor acarbose improved reproductive endocrine disorders, HI, and IR in women with PCOS compared with a high-fibre diet alone [195]. Animal studies have shown that aloe gel extract can act as a potential metabolic regulator of PCOS by controlling glucose homoeostasis, improving insulin secretion, and enhancing insulin-mediated glucose uptake to reduce glucose tolerance [221, 222]. Clinical trials have also shown that l-carnitine supplementation effectively improves PCOS-IR by improving fatty acid β-oxidation and carbohydrate metabolism [194, 195, 221]. A recent trial showed that metformin combined with pioglitazone and acetylcarnitine improved IR and ovulation in women with PCOS more than metformin plus pioglitazone [199].

Traditional Chinese medicine

Traditional Chinese medicine (TCM) is often an important complement to modern Western medicine. Compounds isolated from Chinese herbs are particularly beneficial in improving metabolic disorders. Berberine (BBR) is an alkaloid that can relieve IR and treat PCOS by acting on a variety of insulin signalling pathways, including PPAR, MAPK, and AMPK. In recent years, it has been regarded as a safe and effective insulin sensitizer, although clinical data are lacking. BBR in combination with metformin appears to improve insulin sensitivity more [200–202]. Plant polysaccharides have many different pharmacological effects, and Dendrobium officinale has been shown to be effective in alleviating IR in PCOS [203]. Astragalus polysaccharides may improve insulin sensitivity in PCOS model rats by upregulating serum adiponectin levels and it may play an important role in the treatment of IR [204]. In clinical trial studies, saffron had a significant protective effect on FBG, HOMA-IR, and inflammatory levels of women with PCOS [205, 206]. Pharmacological studies have also found that hehuan yin tang and yijing tang, as key components of various TCM prescriptions, can regulate androgen and insulin levels and improve PCOS-IR symptoms through various pharmacological pathways [207, 223].

Acupoint application was also effective in improving metabolism and IR in obese women with PCOS [205, 224]. Acupuncture is an important component of TCM. Systematic evaluation and some studies have shown that electroacupuncture may increase systemic glucose uptake and improve insulin sensitivity by activating the PCOS sympathetic nervous system and part of the parasympathetic nervous system [208–211], but it may not be as effective as metformin in improving insulin sensitivity in women with PCOS [212]. More large-sample clinical trials are needed to explore TCM as a potential treatment option for PCOS.

Conclusion

In general, women with PCOS develop IR owing to abnormal insulin signalling and metabolic dysfunction in insulin-responsive tissues, with a high incidence of IR in PCOS and a significant negative impact on health. Here, we discuss the molecular mechanisms, diagnosis, and protocol of IR-based PCOS. The pathogenesis of IR in PCOS is not completely clear, and apparently includes genetic and epigenetic changes, deficiency of insulin signal transduction, hyperandrogenaemia, obesity, and inflammation. IR in different PCOS tissues can selectively affect metabolic or mitotic pathways in many tissues, including the ovaries. Therefore, effective prevention and treatment options should be evaluated to improve IR in PCOS patients. Lifestyle interventions and insulin sensitization therapy can be effective strategies for improving insulin sensitivity, while increasing ovulation and reducing androgen levels. Among all of the insulin sensitizers, metformin is the most widely used in PCOS. However, all mentioned drugs for PCOS are still off-label and further studies with larger sample sizes are needed to evaluate the efficacy of these new treatments and provide new insights into the molecular mechanisms of IR in PCOS.

Acknowledgements

AcknowledgementsNone.

Competing interests

Competing interestsThe authors have no conflicts of interest to declare.

References

1. Zawadzki JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. Boston. 1992;77–84.
2. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod (Oxford, England). 2004 doi:10.1093/humrep/deh098 PubMed
3. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale H, Futterweit W. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab. 2006 doi:10.1210/jc.2006-0178 PubMed
4. Bozdag G, Mumusoglu S, Zengin D, Karabulut E, Yildiz B. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod (Oxford, England). 2016 doi:10.1093/humrep/dew218 PubMed
5. Dapas M, Lin F, Nadkarni G, Sisk R, Legro R, Urbanek M. Distinct subtypes of polycystic ovary syndrome with novel genetic associations: an unsupervised, phenotypic clustering analysis. PLoS Med. 2020 doi:10.1371/journal.pmed.1003132 PubMed
6. Yilmaz B, Vellanki P, Ata B, Yildiz B. Diabetes mellitus and insulin resistance in mothers, fathers, sisters, and brothers of women with polycystic ovary syndrome: a systematic review and meta-analysis. Fertil Steril. 2018 doi:10.1016/j.fertnstert.2018.04.024 PubMed
7. Liu Y, Qin Y, Wu B, Peng H, Li M, Luo H. DNA methylation in polycystic ovary syndrome: emerging evidence and challenges. Reprod Toxicol (Elmsford, NY). 2022 doi:10.1016/j.reprotox.2022.04.010 PubMed
8. Merlo E, Silva I, Cardoso R, Graceli J. The obesogen tributyltin induces features of polycystic ovary syndrome (PCOS): a review. J Toxicol Environ Health Part B. 2018 doi:10.1080/10937404.2018.1496214 PubMed
9. Sulaiman M, Al-Farsi Y, Al-Khaduri M, Saleh J, Waly M. Polycystic ovarian syndrome is linked to increased oxidative stress in Omani women. Int J Women’s Health. 2018;10:763–71.10.2147/IJWH.S166461PMC627661530568513 doi:10.2147/IJWH.S166461 PubMed
10. Armanini D, Boscaro M, Bordin L, Sabbadin C. Controversies in the pathogenesis, diagnosis and treatment of PCOS: focus on insulin resistance, inflammation, and hyperandrogenism. Int J Mol Sci. 2022 doi:10.3390/ijms23084110 PubMed
11. Malamouli M, Levinger I, McAinch A, Trewin A, Rodgers R, Moreno-Asso A. The mitochondrial profile in women with polycystic ovary syndrome: impact of exercise. J Mol Endocrinol. 2022 doi:10.1530/JME-21-0177 PubMed
12. Liu Q, Xie Y, Qu L, Zhang M, Mo Z. Dyslipidemia involvement in the development of polycystic ovary syndrome. Taiwan J Obstet Gynecol. 2019 doi:10.1016/j.tjog.2019.05.003 PubMed
13. Sadeghi H, Adeli I, Calina D, Docea A, Mousavi T, Daniali M, et al. Polycystic ovary syndrome: a comprehensive review of pathogenesis, management, and drug repurposing. Int J Mol Sci. 2022;23(2):583.10.3390/ijms23020583PMC877581435054768 doi:10.3390/ijms23020583 PubMed
14. Cassar S, Misso M, Hopkins W, Shaw C, Teede H, Stepto N. Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemic-hyperinsulinaemic clamp studies. Hum Reprod (Oxford, England). 2016 doi:10.1093/humrep/dew243 PubMed
15. Flavia T, Enzo B, Paolo M. Insulin resistance in a large cohort of women with polycystic ovary syndrome: a comparison between euglycaemic-hyperinsulinaemic clamp and surrogate indexes. Hum Reprod. 2017 doi:10.1093/humrep/dex308 PubMed
16. González F, Considine RV, Abdelhadi OA, Acton AJ. saturated fat ingestion promotes lipopolysaccharide- mediated inflammation and insulin resistance in polycystic ovary syndrome. J Clin Endocrinol Metab. 2019 doi:10.1210/jc.2018-01143 PubMed
17. Zhu S, Zhang B, Jiang X, Li Z, Chen ZJ. Metabolic disturbances in non-obese women with polycystic ovary syndrome: a systematic review and meta-analysis. Fertil Steril. 2019 doi:10.1016/j.fertnstert.2018.09.013 PubMed
18. Flavia T, Michela V, Matteo M, Giulia F, Sabrina G, Tom F. Insulin-mediated substrate use in women with different phenotypes of PCOS: the Role of Androgens. J Clin Endocrinol Metab. 2021 doi:10.1210/clinem/dgab380 PubMed
19. Hoeger KM, Dokras A, Piltonen T. Update on PCOS: Consequences, Challenges and Guiding Treatment. Journal of Clinical Endocrinology & Metabolism. 2020.10.1210/clinem/dgaa83933211867 doi:10.1210/clinem/dgaa839 PubMed
20. Moghetti P, Tosi F, Bonin C, Di Sarra D, Fiers T, Kaufman J-M. Divergences in insulin resistance between the different phenotypes of the polycystic ovary syndrome. J Clin Endocrinol Metab. 2013 doi:10.1210/jc.2012-3908 PubMed
21. Bell GA, Sundaram R, Mumford SL. Maternal polycystic ovarian syndrome and early offspring development. Hum Reprod. 2018 doi:10.1093/humrep/dey087 PubMed
22. Chen Y, Guo J, Zhang Q, Zhang C. Insulin resistance is a risk factor for early miscarriage and macrosomia in patients with polycystic ovary syndrome from the first embryo transfer cycle: a retrospective cohort study. Front Endocrinol. 2022 doi:10.3389/fendo.2022.853473 PubMed
23. Hass RK, Dorte G, Mads N, Bo A, Marianne A. Development and risk factors of type 2 diabetes in a nationwide population of women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2017 doi:10.1210/jc.2017-01354 PubMed
24. Wekker V, van Dammen L, Koning A, Heida K, Painter R, Limpens J. Long-term cardiometabolic disease risk in women with PCOS: a systematic review and meta-analysis. Hum Reprod Update. 2020 doi:10.1093/humupd/dmaa029 PubMed
25. Greenwood E, Pasch L, Cedars M, Legro R, Eisenberg E, Huddleston H. Insulin resistance is associated with depression risk in polycystic ovary syndrome. Fertil Steril. 2018 doi:10.1016/j.fertnstert.2018.03.009 PubMed
26. Lee E, Oh B, Lee J, Kimm K, Lee S, Baek K. A novel single nucleotide polymorphism of INSR gene for polycystic ovary syndrome. Fertil Steril. 2008 doi:10.1016/j.fertnstert.2007.05.026 PubMed
27. Colilla S, Cox NJ, Ehrmann DA. Heritability of insulin secretion and insulin action in women with polycystic ovary syndrome and their first degree relatives 1. J Clin Endocrinol Metab. 2001 doi:10.1210/jcem.86.5.7518 PubMed
28. Franks S, Webber L, Goh M, Valentine A, White D, Conway G. Ovarian morphology is a marker of heritable biochemical traits in sisters with polycystic ovaries. J Clin Endocrinol Metab. 2008 doi:10.1210/jc.2008-0369 PubMed
29. Sir-Petermann T, Codner E, Pérez V, Echiburú B, Maliqueo M, Ladrón de Guevara A, et al. Metabolic and reproductive features before and during puberty in daughters of women with polycystic ovary syndrome. J Clin Endocr. 2009;94(6):1923–30.10.1210/jc.2008-2836PMC273034519223518 doi:10.1210/jc.2008-2836 PubMed
30. Xu Y, Qiao J. Association of insulin resistance and elevated androgen levels with Polycystic Ovarian Syndrome (PCOS): a review of literature. J Healthc Eng. 2022 doi:10.1155/2022/9240569 PubMed
31. McAllister J, Legro R, Modi B, Strauss J. Functional genomics of PCOS: from GWAS to molecular mechanisms. Trends Endocrinol Metab. 2015 doi:10.1016/j.tem.2014.12.004 PubMed
32. Jones M, Goodarzi M. Genetic determinants of polycystic ovary syndrome: progress and future directions. Fertil Steril. 2016 doi:10.1016/j.fertnstert.2016.04.040 PubMed
33. Shi Y, Zhao H, Shi Y, Cao Y, Yang D, Li Z. Genome-wide association study identifies eight new risk loci for polycystic ovary syndrome. Nat Genet. 2012 doi:10.1038/ng.2384 PubMed
34. Dakshinamoorthy J, Jain P, Ramamoorthy T, Ayyappan R, Balasundaram U. Association of GWAS identified INSR variants (rs2059807 & rs1799817) with polycystic ovarian syndrome in Indian women. Int J Biol Macromol. 2020 doi:10.1016/j.ijbiomac.2019.10.235 PubMed
35. Mukherjee S, Shaikh N, Khavale S, Shinde G, Meherji P, Shah N. Genetic variation in exon 17 of INSR is associated with insulin resistance and hyperandrogenemia among lean Indian women with polycystic ovary syndrome. Eur J Endocrinol. 2009 doi:10.1530/EJE-08-0932 PubMed
36. Ioannidis A, Ikonomi E, Dimou N, Douma L, Bagos P. Polymorphisms of the insulin receptor and the insulin receptor substrates genes in polycystic ovary syndrome: a Mendelian randomization meta-analysis. Mol Genet Metab. 2010 doi:10.1016/j.ymgme.2009.10.013 PubMed
37. Ruan Y, Ma J, Xie X. Association of IRS-1 and IRS-2 genes polymorphisms with polycystic ovary syndrome: a meta-analysis. Endocr J. 2012 doi:10.1507/endocrj.EJ11-0387 PubMed
38. Roldán B, San Millán J, Escobar-Morreale H. Genetic basis of metabolic abnormalities in polycystic ovary syndrome: implications for therapy. Am J Pharmacogenomics. 2004;4(2):93–107.10.2165/00129785-200404020-0000415059032 doi:10.2165/00129785-200404020-00004 PubMed
39. Hu M, Zhang Y, Guo X, Jia W, Liu G, Zhang J. Hyperandrogenism and insulin resistance induce gravid uterine defects in association with mitochondrial dysfunction and aberrant ROS production. Am J Physiol Endocrinol Metab. 2019 doi:10.1152/ajpendo.00359.2018 PubMed
40. Abbott D, Bacha F. Ontogeny of polycystic ovary syndrome and insulin resistance in utero and early childhood. Fertil Steril. 2013 doi:10.1016/j.fertnstert.2013.05.023 PubMed
41. Jones R, Ozanne S. Fetal programming of glucose–insulin metabolism. Mol Cell Endocrinol. 2009 doi:10.1016/j.mce.2008.06.020 PubMed
42. Pandolfi C, Zugaro A, Lattanzio F, Necozione S, Barbonetti A, Colangeli M. Low birth weight and later development of insulin resistance and biochemical/clinical features of polycystic ovary syndrome. Metabolism. 2008 doi:10.1016/j.metabol.2008.02.018 PubMed
43. Melo A, Vieira C, Barbieri M, Rosa-E-Silva A, Silva A, Cardoso V. High prevalence of polycystic ovary syndrome in women born small for gestational age. Hum Reprod (Oxford, England). 2010 doi:10.1093/humrep/deq162 PubMed
44. Saltiel A, Kahn C. Insulin signalling and the regulation of glucose and lipid metabolism. Nature. 2001 doi:10.1038/414799a PubMed
45. Lee JS, Pilch PF. The insulin receptor: Structure, function, and signaling. Am J Physiol. 1994 doi:10.1152/ajpcell.1994.266.2.C319 PubMed
46. Choi K, Kim Y. Molecular mechanism of insulin resistance in obesity and type 2 diabetes. Korean J Intern Med. 2010 doi:10.3904/kjim.2010.25.2.119 PubMed
47. Xu J, Dun J, Yang J, Zhang J, Lin Q, Huang M. Letrozole rat model mimics human polycystic ovarian syndrome and changes in insulin signal pathways. Med Sci Monit. 2020 doi:10.12659/MSM.923073 PubMed
48. Zeng X, Xie YJ, Liu YT, Long SL, Mo ZC. Polycystic ovarian syndrome: correlation between hyperandrogenism, insulin resistance and obesity. Clin Chim Acta. 2019 doi:10.1016/j.cca.2019.11.003 PubMed
49. Cantley LC, Neel BG. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci. 1999 doi:10.1073/pnas.96.8.4240 PubMed
50. Shaaban Z, Khoradmehr A, Amiri-Yekta A, Nowzari F, JafarzadehShirazi M, Tamadon A. Pathophysiologic mechanisms of insulin secretion and signaling-related genes in etiology of polycystic ovary syndrome. Genetics research. 2021 doi:10.1155/2021/7781823 PubMed
51. Evanthia DK, Andrea D. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev. 2012 doi:10.1210/er.2011-1034 PubMed
52. Nestler JE, Jakubowicz DJ, Aida FDV, Brik C, Quintero N, Medina F. Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system. J Clin Endocrinol Metab. 1998 doi:10.1210/jcem.83.6.4886 PubMed
53. Samuel Varman T, Shulman GI. Mechanisms for insulin resistance: common threads and missing links. Cell. 2012 doi:10.1016/j.cell.2012.02.017 PubMed
54. Zhu S, Li Z, Hu C, Sun F, Wang C, Yuan H. Imaging-based body fat distribution in polycystic ovary syndrome: a systematic review and meta-analysis. Front Endocrinol. 2021 doi:10.3389/fendo.2021.697223 PubMed
55. Kokosar M, Benrick A, Perfilyev A, Nilsson E, Kllman T, Ohlsson C. A single bout of electroacupuncture remodels epigenetic and transcriptional changes in adipose tissue in polycystic ovary syndrome. Sci Rep. 2018 doi:10.1038/s41598-017-17919-5 PubMed
56. Polak A, Adamska A, Krentowska A, Łebkowska A, Hryniewicka J, Adamski M, et al. Body composition, serum concentrations of androgens and insulin resistance in different polycystic ovary syndrome phenotypes. J Clin Med. 2020;9(3):732.10.3390/jcm9030732PMC714128832182752 doi:10.3390/jcm9030732 PubMed
57. Pasquali R, Gambineri A. The Endocrine Impact of Obesity and Body Habitus in the Polycystic Ovary Syndrome. Humana Press. 2006.
58. Abel ED, Peroni O, Kim JK, Kim Y-B, Boss O, Hadro E. Adipose-selective targeting of the GLUT4 gene impairs insulin action in muscle and liver. Nature. 2001 doi:10.1038/35055575 PubMed
59. Corbould A. Chronic testosterone treatment induces selective insulin resistance in subcutaneous adipocytes of women. J Endocrinol. 2007 doi:10.1677/joe.1.07070 PubMed
60. Perello M, Castrogiovanni D, Giovambattista A, Gaillard R, Spinedi E. Impairment in insulin sensitivity after early androgenization in the post-pubertal female rat. Life Sci. 2007 doi:10.1016/j.lfs.2007.02.013 PubMed
61. Puttabyatappa M, Lu C, Martin J, Chazenbalk G, Dumesic D, Padmanabhan V. Developmental programming: impact of prenatal testosterone excess on steroidal machinery and cell differentiation markers in visceral adipocytes of female sheep. Reprod Sci (Thousand Oaks, Calif). 2018 doi:10.1177/1933719117746767 PubMed
62. Dicker A, Rydén M, Näslund E, Muehlen I, Wirén M, Lafontan M. Effect of testosterone on lipolysis in human pre-adipocytes from different fat depots. Diabetologia. 2004 doi:10.1007/s00125-003-1324-0 PubMed
63. Paulukinas RD, Mesaros CA, Penning TM. Conversion of classical and 11-oxygenated androgens by Insulin-Induced AKR1C3 in a model of human PCOS Adipocytes. Endocrinology. 2022 doi:10.1210/endocr/bqac068 PubMed
64. O’Reilly M, Kempegowda P, Walsh M, Taylor A, Manolopoulos K, Allwood J, et al. AKR1C3-mediated adipose androgen generation drives lipotoxicity in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2017;102(9):3327–39.10.1210/jc.2017-00947PMC558706628645211 doi:10.1210/jc.2017-00947 PubMed
65. Brochu-Gaudreau K, Rehfeldt C, Blouin R, Bordignon V, Murphy B, Palin M. Adiponectin action from head to toe. Endocrine. 2010 doi:10.1007/s12020-009-9278-8 PubMed
66. Nawrocki AR, Rajala MW, Tomas E, Pajvani UB, Saha AK, Trumbauer ME. Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferator-activated receptor γ Agonists. J Biol Chem. 2006 doi:10.1074/jbc.M505311200 PubMed
67. Kershaw E, Flier J. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 2004 doi:10.1210/jc.2004-0395 PubMed
68. Haiming C. Adipocytokines in obesity and metabolic disease. J Endocrinol. 2014 doi:10.1530/JOE-13-0339 PubMed
69. Zafari Zangeneh F, Naghizadeh M, Masoumi M. Polycystic ovary syndrome and circulating inflammatory markers. Int J Reprod Med. 2017 PubMed
70. DeFronzo R. Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes. 1988;37(6):667–87.10.2337/diab.37.6.6673289989 doi:10.2337/diab.37.6.667 PubMed
71. Dunaif A, Wu X, Lee A, Diamanti-Kandarakis E. Defects in insulin receptor signaling in vivo in the polycystic ovary syndrome (PCOS). Am J Physiol Endocrinol Metab. 2001 doi:10.1152/ajpendo.2001.281.2.E392 PubMed
72. Nilsson E, Benrick A, Kokosar M, Krook A, Lindgren E, Källman T. Transcriptional and epigenetic changes influencing skeletal muscle metabolism in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2018 doi:10.1210/jc.2018-00935 PubMed
73. Corbould A, Kim Y, Youngren J, Pender C, Kahn B, Lee A. Insulin resistance in the skeletal muscle of women with PCOS involves intrinsic and acquired defects in insulin signaling. Am J Physiol Endocrinol Metab. 2005 doi:10.1152/ajpendo.00361.2004 PubMed
74. Corbould A, Zhao H, Mirzoeva S, Aird F, Dunaif A. Enhanced mitogenic signaling in skeletal muscle of women with polycystic ovary syndrome. Diabetes. 2006 doi:10.2337/diabetes.55.03.06.db05-0453 PubMed
75. Højlund K, Glintborg D, Andersen N, Birk J, Treebak J, Frøsig C. Impaired insulin-stimulated phosphorylation of Akt and AS160 in skeletal muscle of women with polycystic ovary syndrome is reversed by pioglitazone treatment. Diabetes. 2008 doi:10.2337/db07-0706 PubMed
76. Hansen S, Svendsen P, Jeppesen J, Hoeg L, Andersen N, Kristensen J. Molecular mechanisms in skeletal muscle underlying insulin resistance in women who are lean with polycystic ovary syndrome. J Clin Endocrinol Metab. 2019 doi:10.1210/jc.2018-01771 PubMed
77. Rajkhowa M, Brett S, Cuthbertson DJ, Lipina C, Ruiz-Alcaraz AJ, Thomas GE et al. Insulin resistance in polycystic ovary syndrome is associated with defective regulation of ERK1/2 by insulin in skeletal muscle in vivo. Biochem J. 2009 doi:10.1042/BJ20082176 PubMed
78. Allemand M, Irving B, Asmann Y, Klaus K, Tatpati L, Coddington C. Effect of testosterone on insulin stimulated IRS1 Ser phosphorylation in primary rat myotubes–a potential model for PCOS-related insulin resistance. PLoS ONE. 2009 doi:10.1371/journal.pone.0004274 PubMed
79. Kazemi M, Pierson R, Parry S, Kaviani M, Chilibeck P. Obesity, but not hyperandrogenism or insulin resistance, predicts skeletal muscle mass in reproductive-aged women with polycystic ovary syndrome: A systematic review and meta-analysis of 45 observational studies. Obes Rev. 2021 doi:10.1111/obr.13255 PubMed
80. Hutchison SK, Teede HJ, Rachoń D, Harrison CL, Strauss BJ, Stepto NK. Effect of exercise training on insulin sensitivity, mitochondria and computed tomography muscle attenuation in overweight women with and without polycystic ovary syndrome. Diabetologia. 2012 doi:10.1007/s00125-011-2442-8 PubMed
81. Skov V, Glintborg D, Knudsen S, Jensen T, Kruse T, Tan Q. Reduced expression of nuclear-encoded genes involved in mitochondrial oxidative metabolism in skeletal muscle of insulin-resistant women with polycystic ovary syndrome. Diabetes. 2007 doi:10.2337/db07-0275 PubMed
82. Samuel V, Shulman G. The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux. J Clin Investig. 2016 doi:10.1172/JCI77812 PubMed
83. Deswal R, Yadav A, Dang A. Sex hormone binding globulin - an important biomarker for predicting PCOS risk: a systematic review and meta-analysis. Syst Biol Reprod Med. 2018 doi:10.1080/19396368.2017.1410591 PubMed
84. Michael M, Kulkarni R, Postic C, Previs S, Shulman G, Magnuson M. Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction. Mol Cell. 2000 doi:10.1016/S1097-2765(05)00015-8 PubMed
85. Andrisse S, Feng M, Wang Z, Awe O, Yu L, Zhang H. Androgen-induced insulin resistance is ameliorated by deletion of hepatic androgen receptor in females. FASEB J. 2021 doi:10.1096/fj.202100961R PubMed
86. Cui P, Hu W, Ma T, Hu M, Tong X, Zhang F. Long-term androgen excess induces insulin resistance and non-alcoholic fatty liver disease in PCOS-like rats. J Steroid Biochem Mol Biol. 2021 doi:10.1016/j.jsbmb.2021.105829 PubMed
87. Spremović Rađenović S, Pupovac M, Andjić M, Bila J, Srećković S, Gudović A. Prevalence, risk factors, and pathophysiology of nonalcoholic fatty liver disease (NAFLD) in women with Polycystic Ovary Syndrome (PCOS). Biomedicines. 2022 doi:10.3390/biomedicines10010131 PubMed
88. Targher G, Solagna E, Tosi F, Castello R, Spiazzi G, Zoppini G. Abnormal serum alanine aminotransferase levels are associated with impaired insulin sensitivity in young women with polycystic ovary syndrome. J Endocrinol Invest. 2009 doi:10.1007/BF03345743 PubMed
89. Vassilatou E, Lafoyianni S, Vryonidou A, Ioannidis D, Kosma L, Katsoulis K. Increased androgen bioavailability is associated with non-alcoholic fatty liver disease in women with polycystic ovary syndrome. Human Reprod (Oxford, England). 2010 doi:10.1093/humrep/dep380 PubMed
90. Baranova A, Tran T, Birerdinc A, Younossi Z. Systematic review: association of polycystic ovary syndrome with metabolic syndrome and non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2011 doi:10.1111/j.1365-2036.2011.04579.x PubMed
91. Jeanes Y, Reeves S. Metabolic consequences of obesity and insulin resistance in polycystic ovary syndrome: diagnostic and methodological challenges. Nutr Res Rev. 2017 doi:10.1017/S0954422416000287 PubMed
92. Li Y, Chen C, Ma Y, Xiao J, Luo G, Li Y. Multi-system reproductive metabolic disorder: significance for the pathogenesis and therapy of polycystic ovary syndrome (PCOS). Life Sci. 2019 doi:10.1016/j.lfs.2019.04.046 PubMed
93. Franks S, Gilling-Smith C, Watson H, Willis D. Insulin action in the normal and polycystic ovary. Endocrinol Metab Clin North Am. 1999 doi:10.1016/S0889-8529(05)70074-8 PubMed
94. Rosenfield RL, Ehrmann DA. The Pathogenesis of Polycystic Ovary Syndrome (PCOS). Endocrine Reviews. 2016 doi:10.1210/er.2015-1104 PubMed
95. Wang J, Wu D, Guo H, Li M. Hyperandrogenemia and insulin resistance: the chief culprit of polycystic ovary syndrome. Life Sci. 2019 doi:10.1016/j.lfs.2019.116940 PubMed
96. Sanchez-Garrido M, Tena-Sempere M. Metabolic dysfunction in polycystic ovary syndrome: pathogenic role of androgen excess and potential therapeutic strategies. Mol Metab. 2020 doi:10.1016/j.molmet.2020.01.001 PubMed
97. Zhang C, Hu J, Wang W, Sun Y, Sun K. HMGB1-induced aberrant autophagy contributes to insulin resistance in granulosa cells in PCOS. FASEB J. 2020 doi:10.1096/fj.202000605RR PubMed
98. Rice S, Christoforidis N, Gadd C, Nikolaou D, Seyani L, Donaldson A. Impaired insulin-dependent glucose metabolism in granulosa-lutein cells from anovulatory women with polycystic ovaries. Human Reprod (Oxford, England). 2005 doi:10.1093/humrep/deh609 PubMed
99. Palomba S, Piltonen T, Giudice L. Endometrial function in women with polycystic ovary syndrome: a comprehensive review. Hum Reprod Update. 2021 doi:10.1093/humupd/dmaa051 PubMed
100. Zhang Y, Hu M, Yang F, Zhang Y, Ma S, Zhang D. Increased uterine androgen receptor protein abundance results in implantation and mitochondrial defects in pregnant rats with hyperandrogenism and insulin resistance. J Mol Med (Berl). 2021 doi:10.1007/s00109-021-02104-z PubMed
101. Xue J, Zhang H, Liu W, Liu M, Shi M, Wen Z. Metformin inhibits growth of eutopic stromal cells from adenomyotic endometrium via AMPK activation and subsequent inhibition of AKT phosphorylation: a possible role in the treatment of adenomyosis. Reproduction (Cambridge, England). 2013 doi:10.1530/REP-13-0135 PubMed
102. Kim H, DiVall S, Deneau R, Wolfe A. Insulin regulation of GnRH gene expression through MAP kinase signaling pathways. Mol Cell Endocrinol. 2005 doi:10.1016/j.mce.2005.07.002 PubMed
103. Brüning JC, Gautam D, Burks DJ, Gillette J, Schubert M, Orban PC. Role of brain insulin receptor in control of body weight and reproduction. Science. 2000 doi:10.1126/science.289.5487.2122 PubMed
104. Burks D, Font de Mora J, Schubert M, Withers D, Myers M, Towery H, et al. IRS-2 pathways integrate female reproduction and energy homeostasis. Nature. 2000;407(6802):377–82.10.1038/3503010511014193 doi:10.1038/35030105 PubMed
105. Zheng S-H, Du D-F, Li X-L. Leptin levels in women with polycystic ovary syndrome: a systematic review and a meta-analysis. Reprod Sci. 2017 doi:10.1177/1933719116670265 PubMed
106. Hill J, Elias C, Fukuda M, Williams K, Berglund E, Holland W. Direct insulin and leptin action on pro-opiomelanocortin neurons is required for normal glucose homeostasis and fertility. Cell Metab. 2010 doi:10.1016/j.cmet.2010.03.002 PubMed
107. Adashi E, Hsueh A, Yen S. Insulin enhancement of luteinizing hormone and follicle-stimulating hormone release by cultured pituitary cells. Endocrinology. 1981 doi:10.1210/endo-108-4-1441 PubMed
108. Brothers K, Wu S, DiVall S, Messmer M, Kahn C, Miller R. Rescue of obesity-induced infertility in female mice due to a pituitary-specific knockout of the insulin receptor. Cell Metab. 2010 doi:10.1016/j.cmet.2010.06.010 PubMed
109. Romualdi D, Giuliani M, Draisci G, Costantini B, Cristello F, Lanzone A. Pioglitazone reduces the adrenal androgen response to corticotropin-releasing factor without changes in ACTH release in hyperinsulinemic women with polycystic ovary syndrome. Fertil Steril. 2007 doi:10.1016/j.fertnstert.2006.11.076 PubMed
110. Sar M, Lubahn D, French F, Wilson E. Immunohistochemical localization of the androgen receptor in rat and human tissues. Endocrinology. 1990 doi:10.1210/endo-127-6-3180 PubMed
111. Navarro G, Allard C, Morford J, Xu W, Liu S, Molinas A. Androgen excess in pancreatic β cells and neurons predisposes female mice to type 2 diabetes. JCI Insight. 2018 doi:10.1172/jci.insight.98607 PubMed
112. Shen H, Qiu L, Zhang Z, Qin Y, Cao C, Di W. Genome-wide methylated DNA immunoprecipitation analysis of patients with polycystic ovary syndrome. PLoS ONE. 2013 doi:10.1371/journal.pone.0064801 PubMed
113. Ting W, Yanyan Q, Jian H, Keqin H, Duan M. The relationship between insulin resistance and CpG island methylation of LMNA gene in polycystic ovary syndrome. Cell Biochem Biophys. 2013 doi:10.1007/s12013-013-9602-z PubMed
114. Ilie I, Georgescu C. Polycystic ovary syndrome-epigenetic mechanisms and aberrant MicroRNA. Adv Clin Chem. 2015 doi:10.1016/bs.acc.2015.06.001 PubMed
115. Long W, Zhao C, Ji C, Ding H, Cui Y, Guo X. Characterization of serum microRNAs profile of PCOS and identification of novel non-invasive biomarkers. Cell Physiol Biochem. 2014 doi:10.1159/000358698 PubMed
116. He F, Li Y. Role of gut microbiota in the development of insulin resistance and the mechanism underlying polycystic ovary syndrome: a review. J Ovarian Res. 2020 doi:10.1186/s13048-020-00670-3 PubMed
117. Muscogiuri G, Altieri B, de Angelis C, Palomba S, Pivonello R, Colao A. Shedding new light on female fertility: the role of vitamin D. Rev Endocr Metab Disord. 2017 doi:10.1007/s11154-017-9407-2 PubMed
118. Ciebiera M, Esfandyari S, Siblini H, Prince L, Elkafas H, Wojtyła C. Nutrition in gynecological diseases: current perspectives. Nutrients. 2021 doi:10.3390/nu13041178 PubMed
119. Li S, Zhai J, Chu W, Geng X, Chen Z, Du Y. Altered circadian clock as a novel therapeutic target for constant darkness-induced insulin resistance and hyperandrogenism of polycystic ovary syndrome. Transl Res. 2020 doi:10.1016/j.trsl.2020.02.003 PubMed
120. Pandi-Perumal S, Trakht I, Srinivasan V, Spence D, Maestroni G, Zisapel N. Physiological effects of melatonin: role of melatonin receptors and signal transduction pathways. Prog Neurobiol. 2008 doi:10.1016/j.pneurobio.2008.04.001 PubMed
121. Li C, Shi Y, You L, Wang L, Chen Z. Melatonin receptor 1A gene polymorphism associated with polycystic ovary syndrome. Gynecol Obstet Invest. 2011 doi:10.1159/000323542 PubMed
122. Xu X, Kou L, Wang H, Bo C, Song X. Genetic polymorphisms of melatonin receptors 1A and 1B may result in disordered lipid metabolism in obese patients with polycystic ovary syndrome. Mol Med Rep. 2019 doi:10.3892/mmr.2019.9872 PubMed
123. Yi S, Xu J, Shi H, Li W, Li Q, Sun Y. Association between melatonin receptor gene polymorphisms and polycystic ovarian syndrome: a systematic review and meta-analysis. Biosci Rep. 2020;40(6):BSR20200824.10.1042/BSR20200824PMC731760432463080 doi:10.1042/BSR20200824 PubMed
124. Merhi Z, Kandaraki E, Diamanti-Kandarakis E. Implications and future perspectives of AGEs in PCOS pathophysiology. Trends Endocrinol Metab. 2019 doi:10.1016/j.tem.2019.01.005 PubMed
125. Fenichel P, Chevalier N, Brucker-Davis F. Bisphenol A: an endocrine and metabolic disruptor. Ann Endocrinol. 2013 doi:10.1016/j.ando.2013.04.002 PubMed
126. Yang S, Yang C, Pei R, Li C, Li X, Huang X. Investigation on the association of occupational stress with risk of polycystic ovary syndrome and mediating effects of HOMA-IR. Gynecol Endocrinol. 2018 doi:10.1080/09513590.2018.1460340 PubMed
127. Steegers-Theunissen R, Wiegel R, Jansen P, Laven J, Sinclair K. Polycystic ovary syndrome: a brain disorder characterized by eating problems originating during puberty and adolescence. Int J Mol Sci. 2020;21(21):8211.10.3390/ijms21218211PMC766373033153014 doi:10.3390/ijms21218211 PubMed
128. DeFronzo R, Tobin J, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol. 1979 doi:10.1152/ajpendo.1979.237.3.E214 PubMed
129. Bergman RN. Orchestration of glucose homeostasis: from a small acorn to the California oak. Diabetes. 2007 doi:10.2337/db07-9903 PubMed
130. Amisi C, Ciccozzi M, Pozzilli P. Wrist circumference: a new marker for insulin resistance in African women with polycystic ovary syndrome. World J Diabetes. 2020 doi:10.4239/wjd.v11.i2.42 PubMed
131. Otten J, Ahrén B, Olsson T. Surrogate measures of insulin sensitivity vs the hyperinsulinaemic-euglycaemic clamp: a meta-analysis. Diabetologia. 2014 doi:10.1007/s00125-014-3285-x PubMed
132. Xiang S, Hua F, Tang Y, Jiang X, Zhuang Q, Qian F. Relationship between serum lipoprotein ratios and insulin resistance in polycystic ovary syndrome. Int J Endocrinol. 2012 doi:10.1155/2012/173281 PubMed
133. Ghaffarzad A, Amani R, Mehrzad Sadaghiani M, Darabi M, Cheraghian B. Correlation of serum lipoprotein ratios with insulin resistance in infertile women with polycystic ovarian syndrome: a case control study. Int J Fertil Steril. 2016 doi:10.22074/ijfs.2016.4765 PubMed
134. He H, Feng J, Zhang S, Wang Y, Li J, Gao J. The Apolipoprotein B/A1 Ratio is associated with metabolic syndrome components, insulin resistance, androgen hormones, and liver enzymes in women with polycystic ovary syndrome. Front Endocrinol. 2021 doi:10.3389/fendo.2021.773781 PubMed
135. Chen F, Liao Y, Chen M, Yin H, Chen G, Huang Q. Evaluation of the efficacy of sex hormone-binding globulin in insulin resistance assessment based on HOMA-IR in patients with PCOS. Reprod Sci (Thousand Oaks, Calif). 2021 doi:10.1007/s43032-021-00535-0 PubMed
136. Peng Z, Sun Y, Lv X, Zhang H, Liu C, Dai S. Interleukin-6 levels in women with polycystic ovary syndrome: a systematic review and meta-analysis. PLoS ONE. 2016 doi:10.1371/journal.pone.0148531 PubMed
137. Adamska A, Łebkowska A, Krentowska A, Adamski M, Kowalska I. The association between serum ferritin concentration and visceral adiposity estimated by whole-body DXA scan in women with polycystic ovary syndrome. Front Endocrinol. 2020 doi:10.3389/fendo.2019.00873 PubMed
138. Rizk N, Sharif E. Leptin as well as free leptin receptor is associated with polycystic ovary syndrome in young women. Int J Endocrinol. 2015 doi:10.1155/2015/927805 PubMed
139. Polak K, Czyzyk A, Simoncini T, Meczekalski B. New markers of insulin resistance in polycystic ovary syndrome. J Endocrinol Invest. 2017 doi:10.1007/s40618-016-0523-8 PubMed
140. Amisi C. Markers of insulin resistance in Polycystic ovary syndrome women: an update. World J Diabetes. 2022 doi:10.4239/wjd.v13.i3.129 PubMed
141. Traub M. Assessing and treating insulin resistance in women with polycystic ovarian syndrome. World J Diabetes. 2011 doi:10.4239/wjd.v2.i3.33 PubMed
142. Aly J, Decherney A. Lifestyle modifications in PCOS. Clin Obstet Gynecol. 2021 doi:10.1097/GRF.0000000000000594 PubMed
143. Gu Y, Zhou G, Zhou F, Wu Q, Ma C, Zhang Y. Life modifications and PCOS: old story but new tales. Front Endocrinol. 2022 doi:10.3389/fendo.2022.808898 PubMed
144. Afrin S, AlAshqar A, El Sabeh M, Miyashita-Ishiwata M, Reschke L, Brennan J. Diet and nutrition in gynecological disorders: a focus on clinical studies. Nutrients. 2021 doi:10.3390/nu13061747 PubMed
145. Hirschberg A, Naessén S, Stridsberg M, Byström B, Holtet J. Impaired cholecystokinin secretion and disturbed appetite regulation in women with polycystic ovary syndrome. Gynecol Endocrinol. 2004 doi:10.1080/09513590400002300 PubMed
146. Shang Y, Zhou H, He R, Lu W. Dietary modification for reproductive health in women with polycystic ovary syndrome: a systematic review and meta-analysis. Front Endocrinol. 2021 doi:10.3389/fendo.2021.735954 PubMed
147. Mei S, Ding J, Wang K, Ni Z, Yu J. Mediterranean diet combined with a low-carbohydrate dietary pattern in the treatment of overweight polycystic ovary syndrome patients. Front Nutr. 2022 doi:10.3389/fnut.2022.876620 PubMed
148. Escobar-Morreale H. Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. Nat Rev Endocrinol. 2018 doi:10.1038/nrendo.2018.24 PubMed
149. Richards C, Meah V, James P, Rees D, Lord R. HIIT’ing or MISS’ing the optimal management of polycystic ovary syndrome: a systematic review and meta-analysis of high- versus moderate-intensity exercise prescription. Front Physiol. 2021;12: 715881.10.3389/fphys.2021.715881PMC841563134483969 doi:10.3389/fphys.2021.715881 PubMed
150. Patten R, McIlvenna L, Levinger I, Garnham A, Shorakae S, Parker A. High-intensity training elicits greater improvements in cardio-metabolic and reproductive outcomes than moderate-intensity training in women with polycystic ovary syndrome: a randomized clinical trial. Human Reprod (Oxford, England). 2022 doi:10.1093/humrep/deac047 PubMed
151. Patten R, Boyle R, Moholdt T, Kiel I, Hopkins W, Harrison C. Exercise interventions in polycystic ovary syndrome: a systematic review and meta-analysis. Front Physiol. 2020 doi:10.3389/fphys.2020.00606 PubMed
152. Fernandez R, Moore V, Van Ryswyk E, Varcoe T, Rodgers R, March W. Sleep disturbances in women with polycystic ovary syndrome: prevalence, pathophysiology, impact and management strategies. Nat Sci Sleep. 2018 doi:10.2147/NSS.S127475 PubMed
153. Ibrahim Y, Alorabi M, Abdelzaher W, Toni N, Thabet K, Hegazy A, et al. Diacerein ameliorates letrozole-induced polycystic ovarian syndrome in rats. Biomed Pharmacother. 2022;149:112870.10.1016/j.biopha.2022.11287035367769 doi:10.1016/j.biopha.2022.112870 PubMed
154. Zhu D, Chen Y, Huang J, Deng H, Shen X, Lu D. Effects of metformin on pregnancy outcome, metabolic profile, and sex hormone levels in women with polycystic ovary syndrome and their offspring: a systematic review and meta-analysis. Ann Transl Med. 2022 doi:10.21037/atm-22-909 PubMed
155. Teede H, Misso M, Costello M, Dokras A, Laven J, Moran L. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Clin Endocrinol. 2018 doi:10.1111/cen.13795 PubMed
156. Li Y, Tan J, Wang Q, Duan C, Hu Y, Huang W. Comparing the individual effects of metformin and rosiglitazone and their combination in obese women with polycystic ovary syndrome: a randomized controlled trial. Fertil Steril. 2020 doi:10.1016/j.fertnstert.2019.09.011 PubMed
157. Carvajal R, Rosas C, Kohan K, Gabler F, Vantman D, Romero C. Metformin augments the levels of molecules that regulate the expression of the insulin-dependent glucose transporter GLUT4 in the endometria of hyperinsulinemic PCOS patients. Human Reprod (Oxford, England). 2013 doi:10.1093/humrep/det116 PubMed
158. Chen Z, Wei H, Zhao X, Xin X, Peng L, Ning Y. Metformin treatment alleviates polycystic ovary syndrome by decreasing the expression of MMP-2 and MMP-9 via H19/miR-29b-3p and AKT/mTOR/autophagy signaling pathways. J Cell Physiol. 2019 doi:10.1002/jcp.28594 PubMed
159. Oróstica M, Astorga I, Plaza-Parrochia F, Poblete C, Carvajal R, García V, et al. Metformin treatment regulates the expression of molecules involved in adiponectin and insulin signaling pathways in endometria from women with obesity-associated insulin resistance and PCOS. Int J Mol Sci. 2022;23(7):3922.10.3390/ijms23073922PMC899990835409282 doi:10.3390/ijms23073922 PubMed
160. Sharpe A, Morley L, Tang T, Norman R, Balen A. Metformin for ovulation induction (excluding gonadotrophins) in women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2019 doi:10.1002/14651858.CD013505 PubMed
161. Piątkowska-Chmiel I, Herbet M, Gawrońska-Grzywacz M, Dudka J. Regulation of neuroinflammatory signaling by PPARγ Agonist in mouse model of diabetes. Int J Mol Sci. 2022;23(10):5502.10.3390/ijms23105502PMC914138635628311 doi:10.3390/ijms23105502 PubMed
162. Xu Y, Wu Y, Huang Q. Comparison of the effect between pioglitazone and metformin in treating patients with PCOS:a meta-analysis. Arch Gynecol Obstet. 2017 doi:10.1007/s00404-017-4480-z PubMed
163. Steiner CA, Janez A, Jensterle M, Reisinger K, Forst T, Pfützner A. Impact of treatment with rosiglitazone or metformin on biomarkers for insulin resistance and metabolic syndrome in patients with polycystic ovary syndrome. J Diabetes Sci Technol. 2007 doi:10.1177/193229680700100212 PubMed
164. Salamun V, Jensterle M, Janez A, Vrtacnik BE. Liraglutide increases IVF pregnancy rates in obese PCOS women with poor response to first-line reproductive treatments: a pilot randomized study. Eur J Endocrinol. 2018 doi:10.1530/EJE-18-0175 PubMed
165. Ge J, Wang D, Song W, Shen S, Ge W. The effectiveness and safety of liraglutide in treating overweight/obese patients with polycystic ovary syndrome: a meta-analysis. J Endocrinol Invest. 2022 doi:10.1007/s40618-021-01666-6 PubMed
166. Bednarz K, Kowalczyk K, Cwynar M, Czapla D, Czarkowski W, Kmita D. The Role of Glp-1 receptor agonists in insulin resistance with concomitant obesity treatment in polycystic ovary syndrome. Int J Mol Sci. 2022 doi:10.3390/ijms23084334 PubMed
167. Guo C, Huang T, Chen A, Chen X, Wang L, Shen F, et al. Glucagon-like peptide 1 improves insulin resistance in vitro through anti-inflammation of macrophages. Braz J Med Biol Res. 2016;49(12):e5826.10.1590/1414-431X20165826PMC518885827878229 doi:10.1590/1414-431X20165826 PubMed
168. Knudsen L, Lau J. The discovery and development of liraglutide and semaglutide. Front Endocrinol. 2019 doi:10.3389/fendo.2019.00155 PubMed
169. Devin J, Nian H, Celedonio J, Wright P, Brown N. Sitagliptin decreases visceral fat and blood glucose in women with Polycystic Ovarian Syndrome. J Clin Endocrinol Metab. 2020 doi:10.1210/clinem/dgz028 PubMed
170. Dardi I, Kouvatsos T, Jabbour S. SGLT2 inhibitors. Biochem Pharmacol. 2016 doi:10.1016/j.bcp.2015.09.005 PubMed
171. Yaribeygi H, Sathyapalan T, Maleki M, Jamialahmadi T, Sahebkar A. Molecular mechanisms by which SGLT2 inhibitors can induce insulin sensitivity in diabetic milieu: a mechanistic review. Life Sci. 2020 doi:10.1016/j.lfs.2019.117090 PubMed
172. Tan S, Ignatenko S, Wagner F, Dokras A, Seufert J, Zwanziger D. Licogliflozin versus placebo in women with polycystic ovary syndrome: a randomized, double-blind, phase 2 trial. Diabetes Obes Metab. 2021 doi:10.1111/dom.14495 PubMed
173. Cai M, Shao X, Xing F, Zhang Y, Gao X, Zeng Q. Efficacy of canagliflozin versus metformin in women with polycystic ovary syndrome: a randomized, open-label, noninferiority trial. Diabetes Obes Metab. 2022 doi:10.1111/dom.14583 PubMed
174. Graff S, Mario F, Ziegelmann P, Spritzer P. Effects of orlistat vs. metformin on weight loss-related clinical variables in women with PCOS: systematic review and meta-analysis. Int J Clin Pract. 2016;70(6):450–61.10.1111/ijcp.1278727228266 doi:10.1111/ijcp.12787 PubMed
175. Diamanti-Kandarakis E, Katsikis I, Piperi C, Alexandraki K, Panidis D. Effect of long-term orlistat treatment on serum levels of advanced glycation end-products in women with polycystic ovary syndrome. Clin Endocrinol. 2007 doi:10.1111/j.1365-2265.2006.02693.x PubMed
176. Hutch C, Sandoval D. The Role of GLP-1 in the metabolic success of bariatric surgery. Endocrinology. 2017 doi:10.1210/en.2017-00564 PubMed
177. Pareek M, Schauer PR, Kaplan LM, Leiter LA, Rubino F, Bhatt DL. Metabolic surgery: weight loss, diabetes, and beyond. J Am Coll Cardiol. 2018 doi:10.1016/j.jacc.2017.12.014 PubMed
178. Daigle C, Brethauer S, Tu C, Petrick A, Morton J, Schauer P. Which postoperative complications matter most after bariatric surgery? prioritizing quality improvement efforts to improve national outcomes. Surg Obes Relat Dis. 2018 doi:10.1016/j.soard.2018.01.008 PubMed
179. Switzer NJ, Marcil G, Prasad S, Debru E, Church N, Mitchell P. Long-term hypovitaminosis D and secondary hyperparathyroidism outcomes of the Roux-en-Y gastric bypass: a systematic review. Obes Rev. 2017 doi:10.1111/obr.12525 PubMed
180. Simi G, Genazzani A, Obino M, Papini F, Pinelli S, Cela V. Inositol and in vitro fertilization with embryo transfer. Int J Endocrinol. 2017 doi:10.1155/2017/5469409 PubMed
181. Genazzani A, Santagni S, Ricchieri F, Campedelli A, Rattighieri E, Chierchia E. Myo-inositol modulates insulin and luteinizing hormone secretion in normal weight patients with polycystic ovary syndrome. J Obstet Gynaecol Res. 2014 doi:10.1111/jog.12319 PubMed
182. Kamenov Z, Kolarov G, Gateva A, Carlomagno G, Genazzani A. Ovulation induction with myo-inositol alone and in combination with clomiphene citrate in polycystic ovarian syndrome patients with insulin resistance. Gynecol Endocrinol. 2015 doi:10.3109/09513590.2014.964640 PubMed
183. Gambioli R, Forte G, Buzzaccarini G, Unfer V, Laganà A. Myo-Inositol as a key supporter of fertility and physiological gestation. Pharmaceuticals (Basel, Switzerland). 2021 doi:10.3390/ph14060504 PubMed
184. Dinicola S, Unfer V, Facchinetti F, Soulage C, Greene N, Bizzarri M. Inositols: from established knowledge to novel approaches. Int J Mol Sci. 2021 doi:10.3390/ijms221910575 PubMed
185. Laganà A, Forte G, Bizzarri M, Kamenov Z, Bianco B, Kaya C. Inositols in the ovaries: activities and potential therapeutic applications. Expert Opin Drug Metab Toxicol. 2022 doi:10.1080/17425255.2022.2071259 PubMed
186. Laganà A, Monti N, Fedeli V, Gullo G, Bizzarri M. Does Alpha-lipoic acid improve effects on polycystic ovary syndrome?. Eur Rev Med Pharmacol Sci. 2022 doi:10.26355/eurrev_202202_28116 PubMed
187. Iervolino M, Lepore E, Forte G, Laganà A, Buzzaccarini G, Unfer V. Natural molecules in the management of Polycystic Ovary Syndrome (PCOS): an analytical review. Nutrients. 2021 doi:10.3390/nu13051677 PubMed
188. Özcan P, Fıçıcıoğlu C, Kizilkale O, Yesiladali M, Tok O, Ozkan F. Can Coenzyme Q10 supplementation protect the ovarian reserve against oxidative damage?. J Assist Reprod Genet. 2016 doi:10.1007/s10815-016-0751-z PubMed
189. Rahmani E, Jamilian M, Samimi M, Zarezade Mehrizi M, Aghadavod E, Akbari E. The effects of coenzyme Q10 supplementation on gene expression related to insulin, lipid and inflammation in patients with polycystic ovary syndrome. Gynecol Endocrinol. 2018 doi:10.1080/09513590.2017.1381680 PubMed
190. Samimi M, Zarezade Mehrizi M, Foroozanfard F, Akbari H, Jamilian M, Ahmadi S. The effects of coenzyme Q10 supplementation on glucose metabolism and lipid profiles in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. Clin Endocrinol. 2017 doi:10.1111/cen.13288 PubMed
191. Tefagh G, Payab M, Qorbani M, Sharifi F, Sharifi Y, Ebrahimnegad Shirvani M. Effect of vitamin E supplementation on cardiometabolic risk factors, inflammatory and oxidative markers and hormonal functions in PCOS (polycystic ovary syndrome): a systematic review and meta-analysis. Sci Rep. 2022 doi:10.1038/s41598-022-09082-3 PubMed
192. Izadi A, Ebrahimi S, Shirazi S, Taghizadeh S, Parizad M, Farzadi L. Hormonal and metabolic effects of Coenzyme Q10 and/or Vitamin E in patients with polycystic ovary syndrome. J Clin Endocrinol Metab. 2019 doi:10.1210/jc.2018-01221 PubMed
193. Ahmadi S, Jamilian M, Karamali M, Tajabadi-Ebrahimi M, Jafari P, Taghizadeh M. Probiotic supplementation and the effects on weight loss, glycaemia and lipid profiles in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. Hum Fertil (Camb). 2017 doi:10.1080/14647273.2017.1283446 PubMed
194. Li Y, Tan Y, Xia G, Shuai J. Effects of probiotics, prebiotics, and synbiotics on polycystic ovary syndrome: a systematic review and meta-analysis. Crit Rev Food Sci Nutr. 2021:1–17.10.1080/10408398.2021.195115534287081 doi:10.1080/10408398.2021.1951155 PubMed
195. Wang X, Xu T, Liu R, Wu G, Gu L, Zhang Y. High-fiber diet or combined with acarbose alleviates heterogeneous phenotypes of polycystic ovary syndrome by regulating gut microbiota. Front Endocrinol. 2021 doi:10.3389/fendo.2021.806331 PubMed
196. Samimi M, Jamilian M, Ebrahimi F, Rahimi M, Tajbakhsh B, Asemi Z. Oral carnitine supplementation reduces body weight and insulin resistance in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. Clin Endocrinol. 2016 doi:10.1111/cen.13003 PubMed
197. Petrillo T, Battipaglia C, Virmani M, Genazzani A, Genazzani A. Neuroendocrine effects of carnitines on reproductive impairments. Int J Mol Sci. 2021 doi:10.3390/ijms221910781 PubMed
198. Sangouni A, Pakravanfar F, Ghadiri-Anari A, Nadjarzadeh A, Fallahzadeh H, Hosseinzadeh M. The effect of L-carnitine supplementation on insulin resistance, sex hormone-binding globulin and lipid profile in overweight/obese women with polycystic ovary syndrome: a randomized clinical trial. Eur J Nutr. 2022 doi:10.1007/s00394-021-02659-0 PubMed
199. Tauqir S, Israr M, Rauf B, Malik MO, Shah M. Acetyl-L-Carnitine Ameliorates metabolic and endocrine alterations in women with PCOS: a double-blind randomized clinical trial. Adv Ther. 2021(9).10.1007/s12325-021-01789-534047916 doi:10.1007/s12325-021-01789-5 PubMed
200. Wang Y, Fu X, Xu J, Wang Q, Kuang H. Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome. Sci Rep. 2016 doi:10.1038/srep28089 PubMed
201. Saleem F, Rizvi S. New therapeutic approaches in obesity and metabolic syndrome associated with polycystic ovary syndrome. Cureus. 2017 doi:10.7759/cureus.1844 PubMed
202. Rondanelli M, Riva A, Petrangolini G, Allegrini P, Giacosa A, Fazia T. Berberine phospholipid is an effective insulin sensitizer and improves metabolic and hormonal disorders in women with Polycystic Ovary Syndrome: a one-group pretest-post-test explanatory study. Nutrients. 2021 doi:10.3390/nu13103665 PubMed
203. Chen Y, Song D, Jin WU, Jing Z, Liu L, Jiang R, et al. Improvement effects of Dendrobium candidum on insulin resistance in MKR mice and MIN6 cells. Journal of Jilin University(Medicine Edition). 2018.
204. Wei XJ, Chen XH, Weng XG, Wang T, Wang L. Effects of Astragalus Polysaccharides on the Insulin Resistance in Rats. Chinese Journal of Experimental Traditional Medical Formulae. 2011.
205. Rahmani J, Manzari N, Thompson J, Clark C, Villanueva G, Varkaneh H. The effect of saffron on weight and lipid profile: a systematic review, meta-analysis, and dose-response of randomized clinical trials. Phytother Res. 2019 doi:10.1002/ptr.6420 PubMed
206. Rahimi G, Shams S, Aslani M. Effects of crocin supplementation on inflammatory markers, lipid profiles, insulin and cardioprotective indices in women with PCOS: a randomized, double-blind, placebo-controlled trial. Phytotherapy research : PTR. 2022;36(6):2605–15.10.1002/ptr.747435470916 doi:10.1002/ptr.7474 PubMed
207. Wu Y, Li S, Zhu H, Zhuang Z, Shao M, Chen F. Network pharmacology integrated with experimental validation reveals the regulatory mechanism of action of Hehuan Yin decoction in polycystic ovary syndrome with insulin resistance. J Ethnopharmacol. 2022 doi:10.1016/j.jep.2022.115057 PubMed
208. Raja-Khan N, Stener-Victorin E, Wu X, Legro R. The physiological basis of complementary and alternative medicines for polycystic ovary syndrome. Am J Physiol Endocrinol Metab. 2011;301(1):E1–10.10.1152/ajpendo.00667.2010PMC445992321487075 doi:10.1152/ajpendo.00667.2010 PubMed
209. Jia L, Feng J, Li J, Liu F, Xie L, Luo S. The complementary and alternative medicine for polycystic ovary syndrome: a review of clinical application and mechanism. Evid Based Complement Alternat Med. 2021 doi:10.1155/2021/5555315 PubMed
210. Benrick A, Kokosar M, Hu M, Larsson M, Maliqueo M, Marcondes R. Autonomic nervous system activation mediates the increase in whole-body glucose uptake in response to electroacupuncture. FASEB J. 2017 doi:10.1096/fj.201601381R PubMed
211. Zheng R, Qing P, Han M, Song J, Hu M, Ma H. The effect of acupuncture on glucose metabolism and lipid profiles in patients with PCOS: a systematic review and meta-analysis of randomized controlled trials. Evid Based Complement Alternat Med. 2021 doi:10.1155/2021/5555028 PubMed
212. Wen Q, Hu M, Lai M, Li J, Hu Z, Quan K. Effect of acupuncture and metformin on insulin sensitivity in women with polycystic ovary syndrome and insulin resistance: a three-armed randomized controlled trial. Human Reprod (Oxford, England). 2022 doi:10.1093/humrep/deab272 PubMed
213. Glueck C, Goldenberg N. Characteristics of obesity in polycystic ovary syndrome: Etiology, treatment, and genetics. Metabolism. 2019 doi:10.1016/j.metabol.2018.11.002 PubMed
214. Xing C, Li C, He B. Insulin sensitizers for improving the endocrine and metabolic profile in overweight women with PCOS. J Clin Endocrinol Metab. 2020 doi:10.1210/clinem/dgaa337 PubMed
215. Zhao H, Xing C, Zhang J, He B. Comparative efficacy of oral insulin sensitizers metformin, thiazolidinediones, inositol, and berberine in improving endocrine and metabolic profiles in women with PCOS: a network meta-analysis. Reprod Health. 2021 doi:10.1186/s12978-021-01207-7 PubMed
216. Müller TD, Finan B, Bloom SR, D’Alessio D, Drucker DJ, Flatt PR, et al. Glucagon-like peptide 1 (GLP-1). Molecular Metabolism. 2019;30:72–130.10.1016/j.molmet.2019.09.010PMC681241031767182 doi:10.1016/j.molmet.2019.09.010 PubMed
217. Lee Y-S, Park M-S, Choung J-S, Kim S-S, Oh H-H, Choi C-S. Glucagon-like peptide-1 inhibits adipose tissue macrophage infiltration and inflammation in an obese mouse model of diabetes. Diabetologia. 2012 doi:10.1007/s00125-012-2592-3 PubMed
218. Siamashvili M, Davis S. Update on the effects of GLP-1 receptor agonists for the treatment of polycystic ovary syndrome. Expert Rev Clin Pharmacol. 2021 doi:10.1080/17512433.2021.1933433 PubMed
219. DeFronzo R, Norton L, Abdul-Ghani M. Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. Nat Rev Nephrol. 2017 doi:10.1038/nrneph.2016.170 PubMed
220. Marinkovic-Radosevic J, Cigrovski Berkovic M, Kruezi E, Bilic-Curcic I, Mrzljak A. Exploring new treatment options for polycystic ovary syndrome: review of a novel antidiabetic agent SGLT2 inhibitor. World J Diabetes. 2021 doi:10.4239/wjd.v12.i7.932 PubMed
221. Nampoothiri L, Desai B, Maharjan R. Aloe barbadensis Mill. formulation restores lipid profile to normal in a letrozole-induced polycystic ovarian syndrome rat model. Pharmacognosy Res. 2012 doi:10.4103/0974-8490.94736 PubMed
222. Dey A, Dhadhal S, Maharjan R, Nagar PS, Nampoothiri L. Partially purified non-polar phytocomponents from Aloe barbadensis Mill. gel restores metabolic and reproductive comorbidities in letrozole-induced polycystic ovary syndrome rodent model- an “in-vivo” study. Journal of Ethnopharmacology. 2022;291:115161.10.1016/j.jep.2022.11516135271948 doi:10.1016/j.jep.2022.115161 PubMed
223. Lin Y, Xiang L, Li X, Tang Q, Meng F, Chen W. Exploring the Mechanism of Yi-Jing Decoction in Treating Polycystic Ovary Syndrome by Using Network Pharmacology. Curr Med Chem. 2022.10.2174/092986732966622050818061135532255 doi:10.2174/0929867329666220508180611 PubMed
224. Shao C, Dong W, Zhang H. Application of Guijiaosan Shenque acupoint paste can improve the scores of obesity, endocrine and TCM symptoms in treating obese polycystic ovary syndrome. Am J Transl Res. 2021 PubMed